ストックスクリーナーアプリを入手
0.2792
6.62%
-0.0198
アフターアワーズ：
.27
-0.0092
-3.30%
前日終値:
$0.299
開ける：
$0.3
24時間の取引高:
187.43K
Relative Volume:
0.09
時価総額：
$62.96M
収益：
$74,000
当期純損益:
$-13.43M
株価収益率:
-0.0297
EPS:
-9.4
ネットキャッシュフロー:
$-10.54M
1週間 パフォーマンス:
-13.83%
1か月 パフォーマンス:
-15.78%
6か月 パフォーマンス:
-71.80%
1年 パフォーマンス:
-86.77%
1日の値動き範囲:
$0.27
$0.30
1週間の範囲:
$0.27
$0.325
52週間の値動き範囲:
$0.27
$4.00
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
名前
Cyclacel Pharmaceuticals Inc
セクター
電話
908-517-7330
住所
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
CYCC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CYCC
Cyclacel Pharmaceuticals Inc
|
0.2792 | 62.96M | 74,000 | -13.43M | -10.54M | -9.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2020-04-27 | 再開されました | ROTH Capital | Buy |
| 2018-09-07 | 開始されました | Ladenburg Thalmann | Buy |
| 2015-10-16 | 開始されました | H.C. Wainwright | Buy |
| 2010-02-04 | 開始されました | Roth Capital | Buy |
| 2009-10-28 | 開始されました | Merriman | Buy |
| 2008-08-12 | 開始されました | Piper Jaffray | Buy |
| 2008-03-12 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2008-03-12 | 繰り返されました | Collins Stewart | Buy |
| 2008-03-12 | 繰り返されました | Needham & Co | Buy |
| 2007-11-27 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2007-08-10 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2007-06-04 | 繰り返されました | Needham & Co | Buy |
| 2007-04-23 | 開始されました | Lazard Capital | Buy |
| 2007-04-10 | 開始されました | Cantor Fitzgerald | Buy |
すべてを表示
Cyclacel Pharmaceuticals Inc (CYCC) 最新ニュース
Cyclacel Pharmaceuticals Delays 10-K Filing - TipRanks
CYCC stock touches 52-week low at $0.29 amid sharp annual decline - Investing.com
StockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Financial Contrast: Cellectar Biosciences (NASDAQ:CLRB) versus Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals to offer convertible preferred stock in private placement - MSN
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering Of Convertible Preferred Stock - Marketscreener.com
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Manila Times
Cyclacel's Latest $1M Financing Deal Reveals Extended Survival Strategy Through Q3 2025 - Stock Titan
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by Analysts at StockNews.com - Defense World
Cyclacel Pharmaceuticals’ Change of Control Transaction and Appointment of New Executive Leadership - Global Legal Chronicle
(CYCCP) Trading Advice - news.stocktradersdaily.com
CYCLACEL PHARMACEUTICALS Earnings Preview: Recent $CYCC Insider Trading, Hedge Fund Activity, and More - Nasdaq
StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC) - Defense World
Cyclacel Pharmaceuticals acquires cancer drug assets By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals acquires cancer drug assets - Investing.com
Cyclacel stock plunges to 52-week low at $0.3 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.3 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals (CYCC) to Release Earnings on Tuesday - Defense World
Cyclacel stock plunges to 52-week low of $0.31 amid market challenges - MSN
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.com - Defense World
Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Cyclacel Pharmaceuticals interim CEO David Lazar sells $5.5 million in stock - Investing.com India
Cyclacel Pharmaceuticals Announces New Leadership and Restructuring - TipRanks
Cyclacel Pharmaceuticals Says Datuk Dr.Doris Wong Sing Ee Elected As CEO & Executive Director - Marketscreener.com
Cyclacel Pharmaceuticals Expands Executive Leadership Team - citybiz
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership - The Manila Times
Investor Network: Cyclacel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Who Now Controls Cyclacel? New Investor Takes 70% Ownership in $6.3M Leadership Overhaul - StockTitan
Buffett’s on the Sidelines – Should You Follow? - The Globe and Mail
Spiro Rombotis, CEO of Cyclacel Pharmaceuticals, on Innovative Targeted Therapies for Advanced - DocWire News
Cyclacel Pharmaceuticals amends agreement with CEO By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals amends agreement with CEO - Investing.com
(CYCCP) Trading Report - news.stocktradersdaily.com
Head-To-Head Review: Cyclacel Pharmaceuticals (NASDAQ:CYCC) vs. Silence Therapeutics (NASDAQ:SLN) - Defense World
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $25 million in funding from Helena Special Opportunities LLC - Marketscreener.com
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase - MSN
Cyclacel Pharmaceuticals adjusts shareholder rights, amends stock - Investing.com
Cyclacel Pharmaceuticals, Inc. announced that it expects to receive $8 million in funding -February 03, 2025 - Marketscreener.com
Cyclacel Pharmaceuticals streamlines operations, plans asset purchase By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Inc (CYCC) 財務データ
収益
当期純利益
現金流量
EPS
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):